Dosage and usage of Qfitlia (Fitusiran)

Qfitlia (Fitusiran) is a medicine used to prevent and reduce the frequency of bleeding in people with hemophilia A or B. It is indicated for adults and children 12 years and older. The dosage of Qfitlia is critical to ensure the effectiveness and safety of the treatment. First, Qfitlia is for subcutaneous use only and is recommended under the guidance of a healthcare professional experienced in treating hemophilia or bleeding disorders. The starting dose is 50 mg, injected every two months. It is important to measure antithrombin (AT) activity before starting treatment to ensure it is within a safe range; if AT activity is less than 60%, dosing should not be started.

Patients can continue to use previous clotting factor concentrates or bypass agents for prophylaxis within one week after the first dose, but such prophylaxis should be discontinued seven days after the first dose of Qfitlia. During the course of treatment, AT activity needs to be monitored regularly, especially at the 4th, 12th, 20th and 24th weeks after administration. These time points are also critical opportunities for dose adjustment. If any AT activity below 15% is detected, the dose will need to be reduced and AT activity reassessed within three months of adjustment. If AT activity exceeds 35% after six months and the patient does not achieve satisfactory bleeding control, a dose increase may be considered.

Concerningthe preparation and administration of Qfitlia, providers need to ensure that patients or their caregivers receive appropriate training to properly prepare and administer this medication. Qfitlia can be injected by patients themselves or by a caregiver under adult supervision. The injection site should be the thigh or abdomen (avoiding 2 inches around the belly button), or the outer area of u200bu200bthe patient's upper arm. Injecting Qfitlia into delicate, damaged, or scarred skin must be avoided, and it must not be injected into a vein.

Reference materials:https://www.qfitlia.com/